Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

- PMLiVE

CHMP recommends Travere and CSL Vifor’s Filspari to treat rare kidney disease IgAN

The rare form of kidney disease is estimated to affect around 25 per million adults worldwide

- PMLiVE

The pharma trailblazer’s skill set: forged in rare diseases

There is one very special, overlooked area, in large organisations and small, that builds skills like no other: rare diseases

- PMLiVE

Rare diseases – driving further improvements in patient access

Despite significant strides, many rare disease patients have no licensed treatment options and face high levels of unmet need

- PMLiVE

Overcoming challenges in rare disease research with patients

By Beverly Romero

- PMLiVE

FDA approves Allecra’s combination antibiotic Exblifep for complicated UTIs

Complicated UTIs account for approximately 19% of all healthcare-associated infections

- PMLiVE

BeiGene’s tislelizumab receives CHMP recommendation for non-small cell lung cancer

Lung cancer is the second most common type of cancer and the leading cause of cancer-related death globally

- PMLiVE

ICR study reveals AstraZeneca’s ceralasertib sensitises tumours to immunotherapy

Results showed that the drug stopped tumour growth in more than half of patients

- PMLiVE

VML Health announces trio of appointments to creative leadership team

Mel Routhier, Natxo Diaz and Khalid Latif will lead a specialist creative team spanning three continents

- PMLiVE

Valuable research insights to steer pharma’s HCP engagement impact

By Michelle Kelly

- PMLiVE

Committing to diversity: the key to pharmaceutical supply chain resilience

By Carolyn Riegel

- PMLiVE

How brands can rise to meet consumers’ high self-care expectations

With ‘The Great Deceleration’ – a move towards slow living, and a focus on improving mental wellbeing being two predicted trends this year, does this open the door to a...

Fox&Cat

- PMLiVE

Novo Nordisk and Neomorph enter molecular glue degrader partnership worth over $1.4bn

The companies will work on therapies for cardiometabolic and rare diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links